Ginkgo Bioworks (NYSE:DNA) Shares Down 4.9% Following Insider Selling
Ginkgo Bioworks (NYSE:DNA) Shares Down 4.9% Following Insider Selling
The firm's 50 day moving average is $1.60 and its 200-day moving average is $2.08. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -0.95 and a beta of 0.91. Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) traded down 4.9% during trading on Monday following insider selling activity. The company traded as low as $1.20 and last traded at $1.21. 6,513,955 shares traded hands during trading, a decline of 68% from the average session volume of 20,652,377 shares. The stock had previously closed at $1.27.
銀杏生物工程控股有限公司（紐約證券交易所代碼：DNA-獲得評級）的股票在內幕銷售活動之後的交易期間下跌了 4.9%。該公司的交易價格低至 1.20 美元，最後交易價為 1.21 美元。6,513,955 股在交易過程中交易手數，較 20,652,377 股的平均交易量下降了 68%。該股票之前已收盤 1.27 美元。
Specifically, insider Reshma P. Shetty sold 37,650 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, March 22nd. The shares were sold at an average price of $1.29, for a total value of $48,568.50. Following the transaction, the insider now owns 13,842,904 shares in the company, valued at $17,857,346.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Reshma P. Shetty sold 37,650 shares of the firm's stock in a transaction that occurred on Wednesday, March 22nd. The shares were sold at an average price of $1.29, for a total value of $48,568.50. Following the completion of the transaction, the insider now owns 13,842,904 shares of the company's stock, valued at approximately $17,857,346.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark E. Dmytruk sold 34,588 shares of the firm's stock in a transaction that occurred on Wednesday, January 4th. The stock was sold at an average price of $1.56, for a total transaction of $53,957.28. Following the completion of the transaction, the insider now directly owns 454,549 shares of the company's stock, valued at approximately $709,096.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,838,646 shares of company stock worth $6,635,151. 17.47% of the stock is owned by insiders.
具體來說，內幕人士雷什瑪·謝蒂在 3 月 22 日（星期三）發生的一項交易中出售了 37,650 股銀杏生物製品股票。股票以 1.29 美元的平均價格出售，總價值為 48,568.50 美元。交易完成後，內幕人士現在擁有該公司的 13,842,904 股股份，價值為 17,857,346.16 美元。該交易在向 SEC 提交的文件中披露，該文件可在以下網址獲得： 這個鏈接。在相關消息中，內幕雷什瑪·謝蒂在 3 月 22 日（週三）發生的交易中出售了該公司股票的 37,650 股。股票以 1.29 美元的平均價格出售，總價值為 48,568.50 美元。交易完成後，內幕人士現在擁有該公司股票的 13,842,904 股，價值約為 17,857,346.16 美元。該交易在向美國證券交易委員會提交的文件中披露，該文件可在以下位置獲得： 證券交易所網站。此外，內幕人士馬克·德米特魯克在 1 月 4 日（週三）發生的交易中出售了該公司股票的 34,588 股。該股票以 1.56 美元的平均價格出售，交易總額為 53,957.28 美元。交易完成後，內幕人士現在直接擁有該公司股票的 454,549 股，價值約為 709,096.44 美元。可以找到此次銷售的披露 這裡。在過去的 90 天中，內部人士已經出售了 3,838,646 股價值 6,635,151 美元的公司股票。17.47％ 的股票由內部人士擁有。
Analyst Ratings Changes
分析師等級變更
A number of brokerages have issued reports on DNA. BTIG Research decreased their target price on shares of Ginkgo Bioworks from $4.00 to $3.00 in a research note on Sunday, March 5th. Berenberg Bank began coverage on shares of Ginkgo Bioworks in a research note on Monday, November 28th. They set a "buy" rating and a $6.00 target price for the company. Finally, Raymond James decreased their target price on shares of Ginkgo Bioworks from $6.00 to $5.00 and set an "outperform" rating for the company in a research note on Friday, March 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Ginkgo Bioworks currently has a consensus rating of "Hold" and a consensus target price of $4.39.
許多經紀公司已經發布了有關 DNA 的報告。BTIG 研究公司在 3 月 5 日（星期日）的一份研究報告中，將銀杏生物製品股票的目標價格從 4.00 美元降至 3.00 美元。貝倫伯格銀行開始覆蓋銀杏生物工廠的股份在研究筆記上週一, 11 月 28 日.他們為公司設定了「購買」評級和 6.00 美元的目標價格。最後，雷蒙德·詹姆斯（Raymond James）將銀杏生物製品股票的目標價格從 6.00 美元降至 5.00 美元，並在 3 月 3 日（星期五）的一份研究報告中為該公司設定了「跑贏大市」評級。一位投資分析師對該股票進行了賣出評級，其中一名為持有評級，另外三名則向該公司的股票發出買入評級。根據 MarketBeat.com 的數據，銀杏生物廠目前的共識評級為「持有」，共識目標價為 4.39 美元。
Ginkgo Bioworks Stock Performance
銀杏生物庫存表現
The firm's 50 day moving average is $1.60 and its 200-day moving average is $2.08. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -0.95 and a beta of 0.91.
該公司的 50 日移動平均線為 1.60 美元，而 200 天移動平均線為 2.08 美元。該公司的市值為 255 億美元，股價與收益比為 -0.95，貝塔值為 0.91。
Institutional Investors Weigh In On Ginkgo Bioworks
機構投資者權衡銀杏生物工程
Institutional investors and hedge funds have recently modified their holdings of the business. IFP Advisors Inc lifted its stake in shares of Ginkgo Bioworks by 22.3% in the 3rd quarter. IFP Advisors Inc now owns 81,295 shares of the company's stock valued at $991,000 after purchasing an additional 14,820 shares during the last quarter. Guild Investment Management Inc. raised its holdings in Ginkgo Bioworks by 15.3% in the 3rd quarter. Guild Investment Management Inc. now owns 140,835 shares of the company's stock worth $439,000 after acquiring an additional 18,715 shares during the period. Canada Pension Plan Investment Board raised its holdings in Ginkgo Bioworks by 307.4% in the 3rd quarter. Canada Pension Plan Investment Board now owns 335,700 shares of the company's stock worth $1,047,000 after acquiring an additional 253,300 shares during the period. AJ Wealth Strategies LLC raised its holdings in Ginkgo Bioworks by 5.9% in the 3rd quarter. AJ Wealth Strategies LLC now owns 201,200 shares of the company's stock worth $628,000 after acquiring an additional 11,200 shares during the period. Finally, Lake Street Financial LLC bought a new position in Ginkgo Bioworks in the 3rd quarter worth $31,000. Institutional investors and hedge funds own 61.83% of the company's stock.
機構投資者和對沖基金最近修改了他們對業務的持有情況。IFP 顧問公司在第三季度將銀杏生物工廠股份的股份提升了 22.3％。IFP 顧問公司在上一季度額外購買了 14,820 股股票後，現在擁有該公司 81,295 股股票，價值為 991,000 美元。公會投資管理公司在第三季度將其在銀杏生物工廠的持有量增加了 15.3％。在此期間，公會投資管理公司現在擁有該公司股票的 140,835 股，價值 439,000 萬美元。加拿大退休金計劃投資委員會在第三季度將其在銀杏生物工廠的持有量提高了 307.4％。在此期間，加拿大退休金計劃投資委員會現在擁有該公司股票 335,700 股價值 1,047,000 美元的股份。AJ 財富策略有限責任公司在第三季度將其在銀杏生物工廠的持股量增加了 5.9％。在此期間，AJ 財富策略有限責任公司現在擁有該公司股票的 201,200 股價值 628,000 美元。最後, 湖街金融有限責任公司在第三季度買了一個新的位置在銀杏生物廠價值 $31,000.機構投資者和對沖基金擁有公司股票的 61.83％。
About Ginkgo Bioworks
關於銀杏生物
(Get Rating)
(取得評分)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
銀杏生物控股有限公司與其子公司共同開發細胞編程平台。其平台用於對細胞進行編程，以實現產品的生物生產，例如新穎療法，食品成分和來自石油的化學物質。該公司服務於各種終端市場，包括特殊化學品，農業，食品，消費品和藥品。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 High Yields On Breakout Watch With Analyst Tailwinds
- Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
- 3 Financials The Insiders Are Buying
- Can Carnival Cruise Lines Set Sail For New Highs?
- If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
- 獲取有關銀杏生物製品（DNA）的研究報告
- 3 分析師順風突破手錶上的高收益率
- 賽諾菲，Regeneron 股票流行關於慢性阻塞性肺病治療的重大新聞
- 3 業內人士正在購買的財務
- 嘉年華郵輪公司可以啟航新高嗎？
- 如果安全是您的關注, 然後看看桑迪春天銀行
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
接收銀杏生物日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關銀杏生物及相關公司的最新新聞和分析師評級的簡要每日摘要。
